MARKET

PTGX

PTGX

Protagonist
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.55
-0.08
-0.30%
Closed 16:19 04/16 EDT
OPEN
26.88
PREV CLOSE
26.63
HIGH
26.94
LOW
25.88
VOLUME
212.73K
TURNOVER
--
52 WEEK HIGH
32.10
52 WEEK LOW
6.13
MARKET CAP
1.17B
P/E (TTM)
-13.2684
1D
5D
1M
3M
1Y
5Y
Integrin Alpha 4 Market Size 2021 Analysis by Type and Application, Share, Growth, Manufacturers, Regions & forecast to 2024
The Express Wire · 3d ago
Global IBS Treatment Market Trend Analysis 2021, Product Scope, Business Growth, Top Leading Key Players with Industry Perspectives, Share, Revenues, Impact of Covid-19 and Forecast to 2027
Apr 15, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry. Global “IBS Treatment Market” research...
The Express Wire · 4d ago
Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 04/07 13:47
IBS Treatment Market Size 2021 By Trends Evaluation, Global Growth, Consumer-Demand, Consumption, Recent Developments, Strategies, Market Impact and Forecast till 2026, Says Market Growth Reports
The Express Wire · 04/07 06:56
Hepcidin Market 2021 Production, Revenue, Growth Rate, Price and Gross Margin, Opportunities and Forecast 2027 with Top Growth Companies
Apr 06, 2021 (The Expresswire) -- In 2021 ,, “ Hepcidin Market “ Size, Status and Market Insights, Forecast to 2027 The global Hepcidin market was valued at...
The Express Wire · 04/06 07:46
Hepcidin Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
Apr 05, 2021 (Market Insight Reports) -- Qy research medical answers what are the scenarios for growth and recovery and whether there will be any lasting...
Market Insight Reports · 04/05 11:33
Protagonist Therapeutics (PTGX) Initiated with a Buy at Leerink Partners
Protagonist Therapeutics (PTGX) received a Buy rating and a $41.00 price target from Leerink Partners analyst Joseph Schwartz on March 22. The company's
SmarterAnalyst · 03/25 14:07
Thalassemia Treatment Market Size, Share, Industry Analysis Report by Trends, COVID-19 Impact, Top Players are Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc
Mar 23, 2021 (Heraldkeepers) -- In its latest report on Thalassemia Treatment Market provides a concise analysis of the recent market trends. The report...
Heraldkeepers · 03/23 12:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTGX. Analyze the recent business situations of Protagonist through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTGX stock price target is 37.40 with a high estimate of 53.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 172
Institutional Holdings: 46.59M
% Owned: 106.04%
Shares Outstanding: 43.94M
TypeInstitutionsShares
Increased
49
6.60M
New
47
3.36M
Decreased
21
2.74M
Sold Out
9
381.45K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Harold Selick
President/Chief Executive Officer/Director
Dinesh Patel
Chief Financial Officer/Chief Accounting Officer
Donald Kalkofen
Chief Scientific Officer
David Liu
Vice President
Jami Taylor
Other
Suneel Gupta
Other
Samuel Saks
Independent Director
Bryan Giraudo
Independent Director
Sarah Noonberg
Independent Director
Sarah O'Dowd
Independent Director
William Waddill
Independent Director
Lewis Williams
No Data
About PTGX
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Webull offers kinds of Protagonist Therapeutics Inc stock information, including NASDAQ:PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.